Cost-effectiveness of natriuretic peptide-based screening and collaborative care: A report from the STOP-HF (St Vincent's Screening to Prevent Heart Failure) study

European Journal of Heart Failure

Volumn 17, Issue 7, 2015, Pages 672-679

  Ledwidge, Mark T ^a,b   O'Connell, Eoin ^a   Gallagher, Joseph ^a,b   Tilson, Lesley ^c   James, Stephanie ^a   Voon, Victor ^a,b   Bermingham, Margaret ^d   Tallon, Elaine ^a   Watson, Chris ^b   O'Hanlon, Rory ^a   Barry, Michael ^c   McDonald, Kenneth ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cardiovascular prevention; Cost effectiveness; Heart failure; Left ventricular dysfunction; Natriuretic peptide screening; Primary care

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCREENING; SURVIVAL RATE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATIENT CARE; PREVENTION AND CONTROL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT CARE TEAM; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84947735898     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.286     Document Type: Article

References (28)

1. World Health Organisation Global Health Observatory Data Repository. World Health Organisation. 2014. http://www.who.int/gho/database/en/
2. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M,. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
3. Baxter T, Milner P, Wilson K, Leaf M, Nicholl J, Freeman J, Cooper N,. A cost effective, community based heart health promotion project in England: prospective comparative study. BMJ 1997; 315: 582-585.
4. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey SG,. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011; (1):CD001561.
5. Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes M, Niebauer J, Zwisler AD, Schmid JP,. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 1-17.
6. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S,. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001;(1):CD001800.
7. Muller-Riemenschneider F, Damm K, Meinhard C, Bockelbrink A, Vauth C, Willich SN, Greiner W,. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess 2009; 5:Doc16.
8. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW,. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-2959.
9. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op, Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Guidelines on cardiovascular disease prevention in clinical practice. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U,. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
11. Marshall T., Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease. Inform Prim Care 2006; 14: 85-92.
12. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS,. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55: 1169-1177.
13. Kaptoge S, Di AE, Lowe G, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J,; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
14. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K,. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310: 66-74.
15. Karuppiah S, Graham F, Ledwidge M, Conlon C, Cahill J, O'Loughlin C, McManus J, McDonald K,. Elevated BNP with normal systolic function in asymptomatic individuals at risk for heart failure: a marker of diastolic dysfunction and clinical risk. Ir J Med Sci 2006; 175: 5-13.
16. Claxton K, Walker S, Palmer S, Sculpher M,. Appropriate Perspectives for Health Care Decisions. 54. 2010. University of York, Centre for Health Economics.
17. EuroQoL. 2014. http://www.euroqol.org/about-eq-5d.html.
18. Mark DB, Hlatky MA,. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002; 106: 516-520.
19. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko R, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW,. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975-990.
20. Koelewijn-van Loon MS, van der Weijden T, Ronda G, van Steenkiste B, Winkens B, Elwyn G, Grol R,. Improving lifestyle and risk perception through patient involvement in nurse-led cardiovascular risk management: a cluster-randomized controlled trial in primary care. Prev Med 2010; 50: 35-44.
21. De Smedt SD, Kotseva K, De Bacquer D, Wood D, De Backer G, Dallongeville J, Seppo L, Pajak A, Reiner Z, Vanuzzo D, Georgiev B, Gotcheva N, Annemans L,. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. Eur Heart J 2012; 33: 2865-2872.
22. McGrath ER, Glynn LG, Murphy AW, Conghaile A, Canavan M, Reid C, Moloney B, O'Donnell MJ,. Preventing cardiovascular disease in primary care: role of a national risk factor management program. Am Heart J 2012; 163: 714-719.
23. van Steenkiste B, van der Weijden T, Stoffers HE, Grol R,. Barriers to implementing cardiovascular risk tables in routine general practice. Scand J Prim Health Care 2004; 22: 32-37.
24. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A,. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 2006; 332: 1419.
25. Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rikenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart Fail 2013; 1: 64-71.
26. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ,. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-120.
27. McGrady M, Reid CM, Shiel L, Wolfe R, Boffa U, Liew D, Campbell DJ, Prior D, Stewart S, Krum H,. NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF). Int J Cardiol 2013; 169: 133-138.
28. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M,. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013; 62: 1365-1372.